Sera Prognostics (SERA) Stock Price, News & Analysis

Company Overview

Sera Prognostics, Inc. is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations.

Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.

Key Stats

• Today's Range: $3.30 to $3.50
• 50-Day Range: $2.23 to $3.41
• 52-Week Range: $1.37 to $9.13
• Volume: 76,225 shs
• Average Volume: 119,741 shs
• Market Capitalization: $125.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Sera Prognostics Stock Analysis - MarketRank™

Sera Prognostics scored higher than 23% of companies evaluated by MarketBeat, and ranked 825th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sera Prognostics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sera Prognostics are expected to decrease in the coming year, from ($0.96) to ($0.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sera Prognostics is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sera Prognostics is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sera Prognostics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.27% of the float of Sera Prognostics has been sold short.

Short Interest Ratio / Days to Cover

Sera Prognostics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sera Prognostics has recently decreased by 34.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sera Prognostics does not currently pay a dividend.

Dividend Growth

Sera Prognostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.27% of the float of Sera Prognostics has been sold short.

Short Interest Ratio / Days to Cover

Sera Prognostics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sera Prognostics has recently decreased by 34.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.40

News Sentiment

Sera Prognostics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Sera Prognostics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SERA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,251.00 in company stock.

Percentage Held by Insiders

13.50% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SERA Stock Analysis - Frequently Asked Questions

How have SERA shares performed this year?

Sera Prognostics' stock was trading at $8.14 on January 1st, 2025. Since then, SERA stock has decreased by 59.0% and is now trading at $3.34.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) posted its earnings results on Wednesday, August, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative trailing twelve-month return on equity of 45.86%.
Read the conference call transcript.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Top institutional investors of Sera Prognostics include Aberdeen Group plc (5.91%), AWM Investment Company Inc. (1.81%), Captrust Financial Advisors (1.60%) and Geode Capital Management LLC (0.80%). Insiders that own company stock include Zhenya Lindgardt, Austin Aerts, Paul Kearney, John J Boniface, Robert Gardner Harrison, Mansoor Raza Mirza and Joshua Phillips.
View institutional ownership trends.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sera Prognostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:SERA
• CIK: 1534969
• Web: www.seraprognostics.com
• Phone: 801-990-0520
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.90 million
• Net Margins: -30,306.48%
• Pretax Margin: -30,306.48%
• Return on Equity: -45.86%
• Return on Assets: -34.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.73
• Quick Ratio: 1.73

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 1,572.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 37,670,000
• Free Float: 32,587,000
• Market Cap: $125.82 million
• Optionable: Optionable
• Beta: 1.00